• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-K filed by Catalent Inc.

    8/30/24 4:16:50 PM ET
    $CTLT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CTLT alert in real time by email
    NT 10-K 1 d887351dnt10k.htm NT 10-K NT 10-K
    SEC FILE NUMBER  
    001-36587  
    CUSIP NUMBER    
    148806102  

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 12b-25

     

     

    NOTIFICATION OF LATE FILING

     

    (Check one):   

    ☒ Form 10-K  ☐ Form 20-F  ☐ Form 11-K  ☐ Form 10-Q

    ☐ Form 10-D  ☐ Form N-CEN  ☐ Form N-CSR

      For Period Ended: June 30, 2024
      ☐ Transition Report on Form 10-K
      ☐ Transition Report on Form 20-F
      ☐ Transition Report on Form 11-K
      ☐ Transition Report on Form 10-Q
      For the Transition Period Ended:      

     

     

    Read Instruction (on back page) Before Preparing Form. Please Print or Type.

    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

    PART I — REGISTRANT INFORMATION

    Catalent, Inc.

    Full Name of Registrant

    N/A

    Former Name if Applicable

    14 Schoolhouse Road

    Address of Principal Executive Office (Street and Number)

    Somerset, NJ 08873

    City, State and Zip Code

    PART II — RULES 12b-25(b) AND (c)

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     

    ☒     (a)   The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
      (b)   The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
      (c)   The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

    PART III — NARRATIVE

    State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

    Catalent, Inc. (the “Company”) has determined that it is unable to file, without unreasonable effort or expense, its Annual Report on Form 10-K for the fiscal year ended June 30, 2024 (the “Form 10-K”) by the prescribed filing due date of August 29, 2024 because the Company requires additional time to complete certain processes and closing procedures. The Company is working diligently and expects to file the Form 10-K on or before the expiration of the fifteen calendar day extension period provided in Rule 12b-25 of the Securities Exchange Act of 1934, as amended.

    Based on currently available information and subject to the completion of the procedures described above, the Company does not expect any material change to the financial results to be included in the Form 10-K compared to the financial information reported in the earnings release the Company furnished to the Securities and Exchange Commission on the Current Report on Form 8-K filed on August 29, 2024.

    PART IV — OTHER INFORMATION

     

    (1)       Name and telephone number of person to contact in regard to this notification
        Matti Masanovich       732       537-6200
        (Name)     (Area Code)     (Telephone Number)
    (2)     Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). Yes ☒ No ☐
         
    (3)     Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? Yes ☐ No ☒
        If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
        Forward-Looking Statements
        This Notification of Late Filing on Form 12b-25 (“Form 12b-25”) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the expected timing of filing the Form 10-K and the Company’s expected financial results to be included in the Form 10-K. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual future events, results or achievements to be materially different from the Company’s expectations and projections expressed or implied by the forward-looking statements. The important factors include, but are not limited to, the finalization of the Company’s financial statements, completion of the Company’s closing processes and procedures, as well as the general business, financial and accounting risks and the other important factors discussed under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended June 30, 2023, filed with the SEC on December 8, 2023, and the Company’s other filings with the SEC. These forward-looking statements speak only as of the date of this Form 12b-25 and are based on information available to the Company as of the date of this Form 12b-25, and the Company assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.

     

     

    Catalent, Inc.

    (Name of Registrant as Specified in Charter)

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date August 30, 2024     By  

    /s/ Matti Masanovich

    INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.

     

     

    ATTENTION

     

    Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

     

     

     

     

    Get the next $CTLT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CTLT

    DatePrice TargetRatingAnalyst
    11/16/2023$45.00 → $53.00Neutral → Outperform
    Robert W. Baird
    9/5/2023$62.00Hold → Buy
    Argus
    7/20/2023$43.00Equal Weight
    Wells Fargo
    7/5/2023$45.00Neutral
    JP Morgan
    6/14/2023$45.00 → $44.00Buy → Hold
    Jefferies
    5/22/2023$90.00 → $45.00Overweight → Neutral
    JP Morgan
    5/15/2023$55.00 → $29.00Buy → Hold
    Deutsche Bank
    5/8/2023$28.00Neutral → Underperform
    BofA Securities
    More analyst ratings

    $CTLT
    SEC Filings

    View All

    SEC Form 15-12G filed by Catalent Inc.

    15-12G - Catalent, Inc. (0001596783) (Filer)

    12/30/24 8:00:08 AM ET
    $CTLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form POSASR filed by Catalent Inc.

    POSASR - Catalent, Inc. (0001596783) (Filer)

    12/18/24 10:38:20 AM ET
    $CTLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Catalent Inc.

    S-8 POS - Catalent, Inc. (0001596783) (Filer)

    12/18/24 10:33:58 AM ET
    $CTLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTLT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Catalent Announces New Board Appointments

    Adds three new directors with deep expertise across biopharma and life sciences Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it has appointed Susan Mahony, Marie-France Tschudin and Tim Walbert to its Board of Directors as the company continues its growth under Novo Holdings' ownership. Alessandro Maselli, President and CEO, and Board member of Catalent, said "I am excited to work closely with these new Board members as we drive continued growth as an independent CDMO delivering unparalleled service to our pharma and biotech customers. Susan, Marie-France and Tim are each accomplished leaders who bring

    2/20/25 9:00:00 AM ET
    $CTLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lennox International Set to Join S&P 500 and BILL Holdings to Join S&P MidCap 400

    NEW YORK, Dec. 18, 2024 /PRNewswire/ -- S&P MidCap 400 constituent Lennox International Inc. (NYSE:LII) will replace Catalent Inc. (NYSE:CTLT) in the S&P 500, and BILL Holdings Inc. (NYSE:BILL) will replace Lennox International in the S&P MidCap 400 effective prior to the opening of trading on Monday, December 23. Novo Holdings A/S has acquired Catalent in a deal that closed today, December 18. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector Dec 23, 2024 S&P 500 Addition Lennox International LII Industrials Dec 23, 2024 S&P 500 Deletion Catalent CTLT Health

    12/18/24 5:46:00 PM ET
    $BILL
    $CTLT
    $LII
    EDP Services
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Novo Holdings Completes Acquisition of Catalent

    Catalent to Strengthen its Leading Position as a Global Service Provider for the Pharma and Biotech Industry under Private Ownership Catalent, Inc. ("Catalent"), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S ("Novo Holdings"), a global life sciences investment firm, today announced that Novo Holdings has completed its previously announced acquisition of Catalent in an all-cash transaction with a total enterprise value of approximately $16.5 billion. Alessandro Maselli, who will remain President and Chief Executive Officer of Catalent, said, "The completion of this transaction marks a significant milestone for Catalent.

    12/18/24 8:57:00 AM ET
    $CTLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTLT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Catalent upgraded by Robert W. Baird with a new price target

    Robert W. Baird upgraded Catalent from Neutral to Outperform and set a new price target of $53.00 from $45.00 previously

    11/16/23 7:14:33 AM ET
    $CTLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Catalent upgraded by Argus with a new price target

    Argus upgraded Catalent from Hold to Buy and set a new price target of $62.00

    9/5/23 9:11:57 AM ET
    $CTLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on Catalent with a new price target

    Wells Fargo initiated coverage of Catalent with a rating of Equal Weight and set a new price target of $43.00

    7/20/23 7:49:40 AM ET
    $CTLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTLT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Group Pres. Pharma & Consumer Gennadios Aristippos returned 135,286 shares to the company and was granted 21,562 shares, closing all direct ownership in the company (SEC Form 4)

    4 - Catalent, Inc. (0001596783) (Issuer)

    12/18/24 2:10:11 PM ET
    $CTLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Group President, Biologics Mcerlane David returned 47,730 shares to the company and was granted 11,426 shares, closing all direct ownership in the company (SEC Form 4)

    4 - Catalent, Inc. (0001596783) (Issuer)

    12/18/24 2:07:42 PM ET
    $CTLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Accounting Officer Hatzfeld Michael returned 16,676 shares to the company and was granted 3,144 shares, closing all direct ownership in the company (SEC Form 4)

    4 - Catalent, Inc. (0001596783) (Issuer)

    12/18/24 2:05:24 PM ET
    $CTLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTLT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Catalent Inc.

    SC 13G/A - Catalent, Inc. (0001596783) (Subject)

    11/14/24 4:35:03 PM ET
    $CTLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Catalent Inc.

    SC 13G/A - Catalent, Inc. (0001596783) (Subject)

    11/14/24 9:50:26 AM ET
    $CTLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Catalent Inc.

    SC 13G/A - Catalent, Inc. (0001596783) (Subject)

    11/13/24 12:52:42 PM ET
    $CTLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTLT
    Financials

    Live finance-specific insights

    View All

    Catalent, Inc. Reports First Quarter Fiscal 2025 Results

    Q1'25 net revenue of $1.02 billion increased 4% as reported and in constant currency(1), compared to Q1'24. Q1'25 net revenue, excluding COVID revenue of ~$30 million in Q1'25 and ~$100 million in Q1'24, increased 13% compared to Q1'24. Q1'25 net loss of $(129) million. Q1'25 Adjusted EBITDA(1) of $125 million increased 11% as reported, or 10% in constant currency, compared to Q1'24. (1) See "Non-GAAP Financial Measures" below and the GAAP to non-GAAP reconciliation provided later in this release. Catalent, Inc. (NYSE:CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced financial results for the first quarter of fisc

    11/5/24 7:00:00 AM ET
    $CTLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Catalent, Inc. Reports Fourth Quarter and Fiscal 2024 Results

    Q4'24 net revenue of $1.30 billion increased 23% as reported, or 24% in constant currency, compared to Q4'23. Organic, constant-currency net revenue increased 24%, compared to Q4'23. Q4'24 net revenue, excluding COVID-related revenue of ~$70 million in Q4'23 and ~$30 million in Q4'24, increased 29% compared to Q4'23. Fiscal 2024 net revenue of $4.38 billion increased 3% as reported, or 2% in constant currency, compared to fiscal 2023. Organic, constant-currency net revenue increased 1% compared to FY'23. FY'24 net revenue, excluding COVID-related revenue of ~$630 million in FY'23 and ~$260 million in FY'24, increased 13% compared to FY'23. Q4'24 net earnings of $23 million

    8/29/24 7:30:00 AM ET
    $CTLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Catalent, Inc. Reports Third Quarter Fiscal 2024 Results

    Q3'24 net revenue of $1.07 billion increased 4% as reported, or 3% in constant currency(1), compared to Q3'23. Q3'24 net revenue, excluding COVID-related revenue of ~$120 million in Q3'23 and ~$60 million in Q3'24, increased 11% compared to Q3'23. Q3'24 net loss of $(101) million compared to $(227) million of net loss in Q3'23. Q3'24 Adjusted EBITDA(1) of $163 million increased 55% as reported, or 53% in constant currency, compared to Q3'23. (1) See "Non-GAAP Financial Measures" below and the GAAP to non-GAAP reconciliation provided later in this release. Catalent, Inc. (NYSE:CTLT) ("Catalent"), the leader in enabling the development and supply of better treatments for patien

    5/8/24 4:15:00 PM ET
    $CTLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTLT
    Leadership Updates

    Live Leadership Updates

    View All

    Catalent Announces New Board Appointments

    Adds three new directors with deep expertise across biopharma and life sciences Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it has appointed Susan Mahony, Marie-France Tschudin and Tim Walbert to its Board of Directors as the company continues its growth under Novo Holdings' ownership. Alessandro Maselli, President and CEO, and Board member of Catalent, said "I am excited to work closely with these new Board members as we drive continued growth as an independent CDMO delivering unparalleled service to our pharma and biotech customers. Susan, Marie-France and Tim are each accomplished leaders who bring

    2/20/25 9:00:00 AM ET
    $CTLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lennox International Set to Join S&P 500 and BILL Holdings to Join S&P MidCap 400

    NEW YORK, Dec. 18, 2024 /PRNewswire/ -- S&P MidCap 400 constituent Lennox International Inc. (NYSE:LII) will replace Catalent Inc. (NYSE:CTLT) in the S&P 500, and BILL Holdings Inc. (NYSE:BILL) will replace Lennox International in the S&P MidCap 400 effective prior to the opening of trading on Monday, December 23. Novo Holdings A/S has acquired Catalent in a deal that closed today, December 18. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector Dec 23, 2024 S&P 500 Addition Lennox International LII Industrials Dec 23, 2024 S&P 500 Deletion Catalent CTLT Health

    12/18/24 5:46:00 PM ET
    $BILL
    $CTLT
    $LII
    EDP Services
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care

    QuidelOrtho Announces Appointment of Two Independent Directors to its Board

    Veteran Healthcare CEOs John R. Chiminski and R. Scott Huennekens Bring Deep Industry Experience, Operational Expertise and Financial Acumen to the QuidelOrtho Board QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the "Board"), effective December 6, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210769572/en/R. Scott Huennekens (Photo: Business Wire) T

    12/10/24 7:00:00 AM ET
    $CTLT
    $HYPR
    $NVST
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medical/Dental Instruments